Anzeige
Mehr »
Login
Donnerstag, 02.04.2020 Börsentäglich über 12.000 News von 624 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0J3QM ISIN: FI0009014377 Ticker-Symbol: OFK 
Tradegate
02.04.20
11:53 Uhr
37,310 Euro
-0,010
-0,03 %
1-Jahres-Chart
ORION OYJ Chart 1 Jahr
5-Tage-Chart
ORION OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
37,370
37,520
17:16
37,200
37,290
17:12

Aktuelle News zur ORION Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ORION Aktie jetzt für 4€ handeln
MoOrion Oyj: Nubeqa (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer193ORION CORPORATION PRESS RELEASE 30 MARCH 2020 at 18.15 EEST Nubeqa (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate...
► Artikel lesen
19.03.Orion Oyj: Orion cancels its Annual General Meeting on Wednesday 25 March 2020 and postpones it to a later date193ORION CORPORATION STOCK EXCHANGE RELEASE 19 MARCH 2020 at 12.20 EET Orion cancels its Annual General Meeting on Wednesday 25 March 2020 and postpones it to a later date Due...
► Artikel lesen
09.03.Nanoform, Orion Enter Next-gen Drug Development Pact-
09.03.Nanoform and Orion Collaborate on Next-generation Drug Development153HELSINKI, March 9, 2020 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, and Orion Corporation, a Finnish pharmaceutical company, today announced a collaboration...
► Artikel lesen
02.03.Orion Oyj: Orion Corporation: Transfer of 94,317 own B shares on 2 March 2020208ORION CORPORATION STOCK EXCHANGE RELEASE 2 MARCH 2020 at 18.50 EET Orion Corporation: Transfer of 94,317 own B shares on 2 March 2020 In accordance with a decision by...
► Artikel lesen
13.02.Orion Oyj: Tero Närvänen is appointed Orion's new Vice President Quality Management as of 1 May 2020189ORION CORPORATION PRESS RELEASE 13 FEBRUARY 2020 at 11.30 EET Tero Närvänen is appointed Orion's new Vice President Quality Management as of 1 May 2020 Tero...
► Artikel lesen
05.02.Orion Oyj: Notice to the Annual General Meeting of Orion Corporation211ORION CORPORATION STOCK EXCHANGE RELEASE 5 FEBRUARY 2020 at 12:15 EET Notice to the Annual General Meeting of Orion Corporation Notice is given to the...
► Artikel lesen
31.01.Orion Oyj: Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer259ORION CORPORATION PRESS RELEASE 31 JANUARY 2020 at 13.30 EET The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended...
► Artikel lesen
30.01.Orion Oyj: Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer196ORION CORPORATION PRESS RELEASE 30 JANUARY 2020 at 8.30 EET Results from the preplanned final overall survival analysis of the Phase III ARAMIS (Androgen Receptor inhibiting...
► Artikel lesen
23.01.Orion Oyj: Marketing authorization granted for darolutamide in Japan409ORION CORPORATION PRESS RELEASE 23 JANUARY 2020 at 8.30 EET The Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for darolutamide...
► Artikel lesen
22.01.Orion Oyj: Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation232ORION CORPORATION STOCK EXCHANGE RELEASE 22 JANUARY 2020 at 12.45 EET Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion...
► Artikel lesen
22.01.Orion Oyj: Orion publishes Financial Statement Release for 2019 on 5 February 2020148ORION CORPORATION PRESS RELEASE 22 JANUARY 2019 at 09.00 EET Orion will publish its Financial Statement Release for 2019 on Wednesday, 5 February 2020 approximately at 12.00 noon...
► Artikel lesen
21.01.Nasdaq Helsinki Ltd: ORION OYJ: SHARE CONVERSION180EXCHANGE NOTICE, JANUARY 21, 2020 SHARES ORION OYJ: SHARE CONVERSION A total of 228,223 A-shares converted into B-shares will be traded together with the old B-shares of Orion Oyj as of January 22...
► Artikel lesen
21.01.Orion Oyj: 228,223 Orion Corporation A shares converted into B shares215ORION CORPORATION STOCK EXCHANGE RELEASE 21 JANUARY 2020 at 9.00 EET 228,223 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles...
► Artikel lesen
31.12.19Lotus to market Orion drugs in Asian markets-
30.12.19Orion Oyj: Lotus to distribute Orion's Stalevo and Comtan drugs in parts of Asia284ORION CORPORATION PRESS RELEASE 30 DECEMBER 2019 at 9.00 EET Orion Corporation ("Orion") and Lotus Pharmaceutical Co., Ltd. ("Lotus") have made a marketing and distribution...
► Artikel lesen
18.12.19Nasdaq Helsinki Ltd: ORION OYJ: SHARE CONVERSION220EXCHANGE NOTICE, DECEMBER 18, 2019 SHARES ORION OYJ: SHARE CONVERSION A total of 33,944 A-shares converted into B-shares will be traded together with the old B-shares of Orion Oyj as of December 19...
► Artikel lesen
18.12.19Orion Oyj: 33,944 Orion Corporation A shares converted into B shares260ORION CORPORATION STOCK EXCHANGE RELEASE 18 DECEMBER 2019 at 10.15 EET 33,944 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles...
► Artikel lesen
09.12.19Orion Oyj: Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND305Orion Corporation Press release 9 December at 10.15 EET Orion has studied the effects of oral levosimendan on respiratory function in patients...
► Artikel lesen
02.12.19Orion Oyj: Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND298Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND Orion Corporation Press release ...
► Artikel lesen
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1